Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.33 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.32 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.32 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.32 |
| ▸ | MMP13 | P45452 | 1/20 | 0.30 |
| ▸ | CA1 | P00915 | 1/20 | 0.30 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
| ▸ | CA7 | P43166 | 1/20 | 0.30 |
| ▸ | CTSD | P07339 | 1/20 | 0.30 |
| ▸ | CTSL | P07711 | 1/20 | 0.30 |
| ▸ | CTSB | P07858 | 1/20 | 0.30 |
| ▸ | CTSS | P25774 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7060767 | 1.00 | AAK1 (0.33) | AAK1HDAC6HDAC1HDAC2MMP13 | |
| SCHEMBL16812743 | 0.83 | CTSS (0.38) | AAK1HDAC6HDAC1HDAC2CTSD | |
| SCHEMBL28505197 | 0.80 | CTSS (0.31) | HDAC6HDAC1HDAC2CTSS | |
| SCHEMBL25177950 | 0.80 | MMP13 (0.36) | AAK1HDAC6HDAC1HDAC2MMP13 | |
| SCHEMBL25536966 | 0.78 | AAK1 (0.35) | AAK1HDAC6HDAC1HDAC2MMP13 | |
| SCHEMBL86238 | 0.78 | AAK1 (0.35) | AAK1HDAC6HDAC1HDAC2MMP13 | |
| SCHEMBL5565289 | 0.78 | AAK1 (0.35) | AAK1HDAC6HDAC1HDAC2MMP13 | |
| SCHEMBL3244669 | 0.77 | DPP4 (0.33) | AAK1HDAC6HDAC1HDAC2 | |
| SCHEMBL19226352 | 0.77 | AAK1 (0.37) | AAK1HDAC6HDAC1HDAC2MMP13 | |
| SCHEMBL20225541 | 0.77 | AAK1 (0.37) | AAK1HDAC6HDAC1HDAC2MMP13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1311265-B1 | PHARMACEUTICAL COMPOSITIONS FOR TREATING NEUROLOGICAL DISORDERS | TARGACEPT INC (US) | 2004-12-29 | — | — | EP | disclosed |
| US-6743812-B1 | 2,3-DIACYLTARTARIC ACID SALTS OF E-METANICOTINE; NERVOUS SYSTEM DISORDERS; AGONISTS OF SPECIFIC NICOTINIC RECEPTOR SUBTYPES | TARGACEPT, INC. | 2004-06-01 | — | — | US | disclosed |
| EP-1317267-A2 | COMPOSITIONS CONTAINING DIACYLTARTARIC SALTS OF (E)-METANICOTINE | Targacept, Inc. (US) | 2003-06-11 | — | — | EP | disclosed |
| EP-1311265-A2 | PHARMACEUTICAL COMPOSITIONS FOR TREATING NEUROLOGICAL DISORDERS | Targacept, Inc. (US) | 2003-05-21 | — | — | EP | disclosed |
| US-20030087915-A1 | Pharmaceutical compositions and methods for use | DULL GARY MAURICE (US) | 2003-05-08 | — | — | US | disclosed |
| US-6492399-B1 | SUCH AS N-METHYL-4-(3-(5-NITRO-6-AMINOPYRIDIN)YL)-3-BUTEN-1-AMINE; NICOTINIC CHOLINERGIC RECEPTOR AGONISTS | TARGACEPT, INC. | 2002-12-10 | — | — | US | disclosed |
| US-6455554-B1 | COMPOUNDS CAPABLE OF AFFECTING NICOTINIC CHOLINERGIC RECEPTORS; TREATOMG CENTRAL NERVOUS SYSTEM DISORDERS | TARGACEPT, INC. | 2002-09-24 | — | — | US | disclosed |
| US-6432954-B1 | CENTRAL NERVOUS SYSTEM DISORDERS | TARGACEPT, INC. | 2002-08-13 | — | — | US | disclosed |
| EP-1185514-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USE | Targacept, Inc. (US) | 2002-03-13 | — | — | EP | disclosed |
| WO-2002005801-A2 | COMPOSITIONS CONTAINING DIACYLTARTARIC SALTS OF (E)-METANICOTINE | TARGACEPT, INC. (US) | 2002-01-24 | — | — | WO | disclosed |
| WO-2002005798-A2 | PHARMACEUTICAL COMPOSITIONS FOR TREATING NEUROLOGICAL DISORDERS | TARGACEPT, INC. (US) | 2002-01-24 | — | — | WO | disclosed |
| WO-2000075110-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USE | TARGACEPT, INC. (US) | 2000-12-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030087915-A1 | Pharmaceutical compositions and methods for use | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CYP4B1, HTR3E | AAK1 4411/4885HDAC6 1411/4885HDAC1 3015/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.